None

FDA Drug Safety Communication: Updated information on 32 mg intravenous ondansetron (Zofran) dose and pre-mixed ondansetron products

The U.S. Food and Drug Administration (FDA) is notifying health care professionals that the 32 mg, single intravenous (IV) dose of the antinausea drug Zofran (ondansetron hydrochloride) will no longer...

FDA: Single IV dose of ondansetron may cause potentially fatal heart rhythms

FDA is alerting healthcare professionals to the possibility that a 32-mg single intravenous dose of ondansetron (Zofran, ondansetron hydrochloride, and generics) could lead to QT interval prolonga...

Sagent unveils Ondansetron Injection, USP

Sagent Pharmaceuticals, a specialty pharmaceutical company, has launched Ondansetron Injection, USP, an antiemetic, in two latex-free vial presentations.

Ondansetron Safe for Fetus, Study Affirms (CME/CE)

(MedPage Today) -- Use of the antiemetic ondansetron during pregnancy was not associated with any adverse fetal outcomes, an observational study showed.

FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran)

The U.S. Food and Drug Administration (FDA) is informing healthcare professionals and the public that preliminary results from a recently completed clinical study suggest that a 32 mg single intraveno...

Is Ondansetron Safe for Preventing Vomiting in Pregnancy?

Andrew Kaunitz, MD, comments on the recent study showing that ondansetron does not have significant adverse effects on the fetus when used to prevent vomiting. Medscape Ob/Gyn

Ondansetron looks safe in pregnancy, so far

N Engl J Med2013;368:814-23The popular antiemetic ondansetron looked safe for pregnant women in a large study from Denmark. The authors found no evidence of harm to the unborn baby in a series of......

Ondansetron Not Associated With Adverse Fetal Events

A population-based Danish study has found no association between the use of ondansetron during pregnancy and adverse fetal events. Medscape Medical News

Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia.

Introduction: Ondansetron is a 5-HT3 receptor antagonist commonly used as an antiemetic to prevent nausea and vomiting associated with anti-cancer drugs, cancer radiotherapy or postoperatively. Recent...

Comparison of ondansetron and metoclopramide antiemetic prophylaxis in maxillofacial surgery patients.

PURPOSE: The purpose of this study was to compare the efficacy of ondansetron and metoclopramide, administered for the prophylaxis of vomiting in patients undergoing oral and maxillofacial surgery und...

Association of ABCB1 polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting.

Summary We investigated whether the 2677G>T/A and 3435C>T polymorphisms of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) affect the efficacy of ondansetron to prevent postoperat...

The Combination of Haloperidol, Dexamethasone, and Ondansetron for Prevention of Postoperative Nausea and Vomiting in Laparoscopic Sleeve Gastrectomy: a Randomized Double-Blind Trial.

BACKGROUND: Many patients may experience postoperative nausea and vomiting (PONV) following laparoscopic sleeve gastrectomy (LSG). We evaluated the efficacy of the combination of haloperidol, dexameth...

Comparison of Dexamethasone with Ondansetron or Haloperidol for Prevention of Patient-Controlled Analgesia-Related Postoperative Nausea and Vomiting: A Randomized Clinical Trial.

BACKGROUND: Patient-controlled analgesia (PCA) with parenteral opioids is associated with a high incidence of postoperative nausea and vomiting (PONV). The aim of the present stu...